Copyright
©The Author(s) 2016.
World J Gastrointest Pathophysiol. May 15, 2016; 7(2): 199-210
Published online May 15, 2016. doi: 10.4291/wjgp.v7.i2.199
Published online May 15, 2016. doi: 10.4291/wjgp.v7.i2.199
Drug | Combination | Phase | Status | Trial ID |
GDC-0449 | Gemcitabine | 0 | N | NCT01713218 |
1/2 | A | NCT01195415 | ||
2 | A | NCT01064622 | ||
Erlotinib, gemcitabine | 1 | A | NCT00878163 | |
Gemcitabine, nab-paclitaxel | 2 | A | NCT01088815 | |
LDE-225 | Gemcitabine, nab-paclitaxel | 1/2 | R | NCT01431794 |
1/2 | R | NCT02358161 | ||
BKM120 | 1 | C | NCT01576666 | |
IPI-926 | Gemcitabine | 1/2 | C | NCT01130142 |
- Citation: Klieser E, Swierczynski S, Mayr C, Jäger T, Schmidt J, Neureiter D, Kiesslich T, Illig R. Differential role of Hedgehog signaling in human pancreatic (patho-) physiology: An up to date review. World J Gastrointest Pathophysiol 2016; 7(2): 199-210
- URL: https://www.wjgnet.com/2150-5330/full/v7/i2/199.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v7.i2.199